Search

Your search keyword '"M S de Bruin-Weller"' showing total 59 results

Search Constraints

Start Over You searched for: Author "M S de Bruin-Weller" Remove constraint Author: "M S de Bruin-Weller" Topic business Remove constraint Topic: business
59 results on '"M S de Bruin-Weller"'

Search Results

1. European Task Force on Atopic Dermatitis

2. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Catalog

Books, media, physical & digital resources

3. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion

4. Conjunctivitis in dupilumab clinical trials

5. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts

6. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

7. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis

8. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement

9. Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine

10. Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?

11. Systemic treatment in atopic dermatitis after 2018: from experienced‐based treatment to evidence‐based treatment?

12. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis

13. European task force on atopic dermatitis position paper

14. Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis

16. P552 RAPIDITY OF EFFICACY RESPONSE WITH ABROCITINIB VERSUS DUPILUMAB IN THE HEAD–NECK REGION (JADE COMPARE)

17. 407 High burden of patient-reported ocular disorders and symptoms in adults with moderate-to-severe atopic dermatitis

18. Epidemiology of atopic dermatitis in adults: Results from an international survey

20. Predicting therapy response to mycophenolic acid using UGT1A9 genotyping : towards personalized medicine in atopic dermatitis

21. 418 Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment

22. 417 The effect of dupilumab on the peripheral blood T cell compartment in moderate to severe atopic dermatitis patients

23. 161 EUROSTAD Prospective Observational Study: Baseline Characteristics, Atopic Dermatitis Severity, and Patient-Reported Outcomes

24. 415 Endotyping of adult and paediatric atopic dermatitis; is it one disease?

25. 427 Predicting treatment response to methotrexate in atopic dermatitis patients using clinical characteristics and serum biomarkers

26. 178 Effect of Dupilumab on Global Individual Signs Score Outcomes in Adults With Moderate-to-Severe Atopic Dermatitis: Combined Results From Four Phase 3 Trials

27. 621 Dupilumab in adolescents with moderate-to-severe atopic dermatitis and a history of inadequate response, or intolerance to cyclosporine: subgroup analysis from a pivotal 16-week trial

28. 714 Productivity losses in adults with atopic dermatitis (AD): A cross-sectional study from clinical practices in Europe and Canada

29. Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity

30. Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study

31. Drug survival of cyclosporine in the treatment of hand eczema : A multicentre, daily use study

32. Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis

33. E-health in caring for patients with atopic dermatitis

34. P479 Dupilumab improves patient-reported outcomes in atopic dermatitis patients inadequately controlled, intolerant, or inadvisable for cyclosporine-A

35. Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis

36. PSS43 - DUPILUMAB IMPROVES ABSENTEEISM IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS COMPARED WITH PLACEBO IN PHASE 3 LIBERTY AD SOLO STUDIES

37. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

38. 489 Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (liberty ad solo 1&2, chromos, cafe)

39. Low bone mineral density in adult patients with moderate to severe atopic dermatitis

40. First experience with enteric-coated mycophenolate sodium (Myfortic®) in severe recalcitrant adult atopic dermatitis: an open label study

41. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis

42. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

43. A panel of biomarkers for disease severity in atopic dermatitis

44. Modulation of the atopy patch test: tacrolimus 0.1% compared with triamcinolone acetonide 0.1%

45. Atopy patch test in patients with atopic eczema/dermatitis syndrome: comparison of petrolatum and aqueous solution as a vehicle

46. Anti-allergic mattress covers in asthma: to do or not to do?

48. The effect of anti-allergic mattress encasings on house dust mite-induced early- and late-airway reactions in asthmatic patients. A double-blind, placebo-controlled study

49. 465 Identification of Atopic Dermatitis endotypes based on serum biomarker analysis

50. The Patient-Reported Disease Burden In Adults With Atopic Dermatitis: A Cross-Sectional Study In Canada and Europe